Terug

Kiadis Pharma N.V.

Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.

  • Publicatie datum 30 sep 2015 - 07:00
  • Statutaire naam Kiadis Pharma N.V.
  • Titel Kiadis Pharma announces initiation of a repeat-dosing Phase II clinical trial with ATIR101™
  • Bericht Amsterdam, The Netherlands, September 30, 2015 – Kiadis Pharma N.V. (“Kiadis Pharma” or “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces that it has obtained regulatory approvals from the national authorities both in Canada and in Belgium to start a further Phase II clinical trial with its lead product ATIR101™. In this new trial the safety and efficacy of using a second dose of ATIR101™ will be studied (NCT02500550 / EudraCT 2015-002821-20).

Gerelateerde downloads

201509290000000010_PR Kiadis Pharma Initiation 008 trial 2015-09-30.docx
201509290000000010_PR Kiadis Pharma Initiation 008 trial 2015-09-30.pdf

Datum laatste update: 26 januari 2022

Informatie delen

Delen via: deel